Month: April 2024

Nanostics Receives Funding from the University of Alberta Innovation Fund to Propel Adoption of the ClarityDX Prostate Test

University of Alberta Innovation Fund invests in Nanostics to support adoption of its ClarityDX Prostate test
ClarityDX Prostate is a blood test that combines biological and clinical information using machine learning to generate a risk score for aggressive prostate cancer

EDMONTON, ALBERTA – April 23 – Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, announced today that it received an investment from the University of Alberta Innovation Fund (UAIF) to help propel adoption of Nanostics’ ClarityDX Prostate® test in North America.

Funds raised through the UAIF will go towards expanding access to ClarityDX Prostate across North America and supporting the expansion of its product pipeline, including the development of ClarityDX Bladder, a minimally invasive bladder cancer diagnostic test.

ClarityDX Prostate is currently available in Canada as a laboratory-developed test. For more information or to order the test please visit nanosticsdx.com.

Click below to read the full press release.

Press Release

Prostate Cancer Screening in 2024

Dr. Chris Wallis talks about the benefits and harms of prostate cancer screening in 2024 using PSA and the addition of adjunctive tests like ClarityDX Prostate.

Video

Prostate cancer screening in 2024

Nanostics and Alberta Health Services collaborate to develop new diagnostic tools for urological diseases

Nanostics and Alberta Health Services (AHS) agreement enables collaboration with AHS data scientists to develop new tools to improve the diagnosis of urological diseases.
This collaboration will leverage Alberta’s comprehensive digital healthcare assets to improve patient care while satisfying all AHS privacy concerns.

EDMONTON, ALBERTA – April 9th, 2024 – Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, is excited to announce a partnership with Cancer Care Alberta, Alberta Health Services (AHS) to leverage advanced data analytics from Connect Care and the Cancer Care Alberta Data Environment for Cancer Inquiries and Decisions (DECIDe). This agreement will streamline access to Connect Care’s powerful and consolidated “one record, one patient, one health clinical information system” to help drive diagnostic and prognostic innovations in urological care in Alberta.